Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Accumulated Expenses (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Accumulated Expenses for 6 consecutive years, with $8.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 15.23% to $8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.3 million through Dec 2025, up 15.23% year-over-year, with the annual reading at $8.3 million for FY2025, 15.23% up from the prior year.
  • Accumulated Expenses hit $8.3 million in Q4 2025 for Rapid Micro Biosystems, up from $6.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.6 million in Q3 2021 to a low of $595000.0 in Q1 2022.
  • Historically, Accumulated Expenses has averaged $7.1 million across 5 years, with a median of $7.2 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: crashed 74.4% in 2022 and later soared 925.88% in 2023.
  • Year by year, Accumulated Expenses stood at $10.9 million in 2021, then dropped by 25.35% to $8.2 million in 2022, then increased by 21.56% to $9.9 million in 2023, then dropped by 27.15% to $7.2 million in 2024, then increased by 15.23% to $8.3 million in 2025.
  • Business Quant data shows Accumulated Expenses for RPID at $8.3 million in Q4 2025, $6.6 million in Q3 2025, and $5.7 million in Q2 2025.